Meeder Asset Management’s Immunovant IMVT Stock Holding History

Meeder Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-192	Closed	-$4.88K	–	960
2025 Q4	$4.88K	Buy	+192	New	+$4.28K	﹤0.01%	795

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Meeder Asset Management's IMVT Position: Q1 2026 in Review

Meeder Asset Management sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 192 shares — an estimated $4.88K sold.

Meeder Asset Management first reported a position in IMVT in Q4 2025 and held it in 1 quarter. The position peaked at $4.88K in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Meeder Asset Management reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
Meeder Asset Management sold 192 Immunovant shares in Q1 2026, an estimated $4.88K.
Meeder Asset Management first reported a position in Immunovant in Q4 2025 and held it in 1 quarter.
Meeder Asset Management's Immunovant position peaked at $4.88K in Q4 2025.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.